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Chronic obstructive pulmonary disease (COPD) is a common, complex disease associated with substantialmorbidity
and mortality. COPD is defined by irreversible airflow obstruction; airflow obstruction is typically determined by
reductions in quantitative spirometric indices, including forced expiratory volume at 1 s (FEV1) and the ratio of
FEV1 to forced vital capacity (FVC). To identify genetic determinants of quantitative spirometric phenotypes, an
autosomal 10-cM genomewide scan of short tandem repeat (STR) polymorphic markers was performed in 72
pedigrees (585 individuals) ascertained through probands with severe early-onset COPD. Multipoint variance-
component linkage analysis (using SOLAR) was performed for quantitative phenotypes, including FEV1, FVC, and
FEV1/FVC. In the initial genomewide scan, significant evidence for linkage to FEV1/FVC was demonstrated on
chromosome 2q (LOD score 4.12 at 222 cM). Suggestive evidence was found for linkage to FEV1/FVC on chro-
mosomes 1 (LOD score 1.92 at 120 cM) and 17 (LOD score 2.03 at 67 cM) and to FVC on chromosome 1 (LOD
score 2.05 at 13 cM). The highest LOD score for FEV1 in the initial genomewide scan was 1.53, on chromosome
12, at 36 cM. After inclusion of 12 additional STR markers on chromosome 12p, which had been previously
genotyped in this population, suggestive evidence for linkage of FEV1 (LOD score 2.43 at 37 cM) to this region
was demonstrated. These observations provide both significant evidence for an early-onset COPD-susceptibility
locus on chromosome 2 and suggestive evidence for linkage of spirometry-related phenotypes to several other
genomic regions. The significant linkage of FEV1/FVC to chromosome 2q could reflect one or more genes influencing
the development of airflow obstruction or dysanapsis.
Introduction
Chronic obstructive pulmonary disease (COPD) is a
common, complex disease associated with substantial
morbidity and mortality (Hoyert et al. 1999). Cigarette
smoking is the major environmental determinant of
COPD (Davis and Novotny 1989). However, the de-
velopment of chronic airflow obstruction—the defining
characteristic of COPD—is quite variable among smok-
ers (Silverman and Speizer 1996). Airflow obstruction
is typically assessed by spirometry. Spirometry involves
forced expiratory maneuvers after the subject has in-
haled to total lung capacity. Individuals with airflow
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obstruction have reductions in the forced expiratory vol-
ume at 1 s (FEV1) and in the ratio of FEV1 to forced
vital capacity (FVC).
Severe alpha 1-antitrypsin (AAT) deficiency is a
proven but uncommon genetic determinant of COPD
(Larsson 1978; Tobin et al. 1983; Janus et al. 1985).
Several types of studies have suggested that genetic fac-
tors other than AAT deficiency may be involved in the
susceptibility to develop COPD (Lomas and Silverman
2001). Studies of spirometric measurements performed
in the general population and in twins have suggested
that genetic factors influence variation in pulmonary
function (Redline et al. 1989). Studies in relatives of
patients with COPD also have supported a role for ge-
netic factors (Cohen et al. 1977; Kueppers et al. 1977;
Cohen 1980; Beaty et al. 1987).
To identify genomic regions linked to COPD-related
phenotypes, we have enrolled pedigrees ascertained
through single probands who had severe early-onset
COPD but who did not have severe AAT deficiency. In
these families, we have previously demonstrated in-
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Table 1
Demographics and Spirometry in Families with Early-Onset COPD
GROUP (NO.
OF INDIVIDUALS)
MEAN  SD
Age Pack-Years
FEV1
(% of Predicted Value)
FVC
(% of Predicted Value)
FEV1/FVC
(% of Predicted Value)
Probands (72) 47.7  5.3 38.9  21.6 17.3  6.3 47.9  14.7 37.4  11.4
Siblings (148) 47.0  9.0 22.2  20.9 80.8  22.8 93.9  18.3 85.1  15.2
Parents (48) 72.5  8.1 38.0  39.4 65.3  25.0 81.2  19.1 77.6  17.9
Children (124) 24.7  5.7 4.3  6.3 90.9  11.6 98.0  11.3 92.6  7.8
Other relatives (160) 54.2  18.0 23.1  25.7 82.1  19.1 91.3  14.8 89.0  11.9
Spouses (30) 51.8  6.1 37.4  35.0 85.5  23.1 95.1  18.7 89.5  13.3
creased risk, to current or ex-smoking first-degree rel-
atives of probands with early-onset COPD, for airflow
obstruction, chronic bronchitis, and increased bron-
chodilator responsiveness (Silverman et al. 1998; Ce-
ledon et al. 1999). In addition, a previous genome-scan
linkage analysis of qualitative COPD-related pheno-
types in the same data set provided suggestive evidence
for linkage of airflow obstruction to chromosome 12p
and of chronic bronchitis to chromosome 22q (Silver-
man et al. 2002). We now report the linkage-analysis
results of an autosomal genomewide scan, using quan-
titative spirometric phenotypes in extended pedigrees of
individuals with severe early-onset COPD.
Subjects and Methods
Subjects
The recruitment and assessment of probands with se-
vere early-onset COPD has been described elsewhere
(Silverman et al. 1998, 2000). In brief, ascertainment
criteria for probands with severe early-onset COPD in-
cluded (1) FEV1 !40% of predicted value, (2) age !53
years, and (3) absence of severe AAT deficiency (e.g., PI
Z, PI null-null). The age threshold of 53 years was cho-
sen at the initiation of study enrollment, to balance our
goal of identifying very young probands against our need
to ascertain an adequate number of probands. All avail-
able first-degree relatives and older second-degree rela-
tives (half sibs, aunts, uncles, and grandparents) of the
ascertained probands with COPD were invited to par-
ticipate. In addition to those enrolled on the basis of this
fixed, single-ascertainment scheme, 49 additional rela-
tives were enrolled, including (a) 37 first-degree relatives
of pedigree members with moderate airflow obstruction
(FEV1 !60% of predicted value and FEV1/FVC !90%
of predicted value), (b) 3 other relatives who had been
diagnosed with COPD, (c) 2 first-degree relatives of una-
vailable reportedly affected pedigree members, and (d)
7 other relatives. Seventy-two pedigrees with mean size
of 8.1 individuals (range 2–18) were included in the
genome-scan linkage analysis.
Participants gave written informed consent and com-
pleted a protocol that included a questionnaire, spirom-
etry, and a blood sample. The study protocol was ap-
proved by the human research committees of Partners
Health Care (Brigham and Women’s Hospital and Mas-
sachusetts General Hospital) and the Brockton/West
Roxbury Veterans Administration Hospital.
Questionnaire
Each participant completed a modified version of the
1978 American Thoracic Society–Division of Lung Dis-
eases Epidemiology Questionnaire, which has been de-
scribed elsewhere (Ferris 1978; Silverman et al. 1998).
Pack-years of cigarette smoking were calculated as the
product of the average number of cigarettes smoked per
day—which was divided by 20, to convert to packs—
and the duration of smoking (in years).
Pulmonary Function Tests
Pulmonary function testing in these pedigrees has been
described elsewhere (Silverman et al. 1998, 2000). In
brief, spirometry was performed with a Survey Tach Spi-
rometer (Warren E. Collins), in accordance with Amer-
ican Thoracic Society guidelines (1995). Subjects were
instructed to withhold, if possible, bronchodilator med-
ications for at least 4 h before spirometry. Although the
absolute-volume measurements were the primary phe-
notypes analyzed, pulmonary function test results also
were expressed as percentage of predicted values by use
of equations formulated by Crapo et al. (1981) for white
adult participants. For white participants of age !18
years, predicted values for FEV1 were determined from
equations developed by Hsu et al. (1979), and predicted
values for FEV1/FVC were determined from equations
developed by Knudson et al. (1983). For African-Amer-
ican participants, predicted spirometric values were de-
termined from equations developed by Hankinson et al.
(1999). For seven subjects, previously obtained pul-
monary function test results were used, since three of
them had undergone lung volume–reduction surgery and
four resided at great geographic distance. Spirometry
values for three other subjects were unavailable.
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Table 2
Genome-Scan Multipoint Linkage Analysis with SOLAR:
Chromosomal Regions with LOD Scores 11.0
CHROMOSOME
MAXIMUM LOD SCORE (LOCATION)a
FEV1 FVC FEV1/FVC
1 1.28 (139) 2.05 (13) 1.92 (120)
2 1.12 (222) .59 (40) 4.12 (222)
3 1.10 (213) .50 (209) .64 (219)
4 1.15 (60) .94 (60) .99 (92)
8 1.11 (164) 1.84 (164) 1.10 (53)
11 .21 (85) 1.53 (85) .32 (21)
12 1.53 (36) 1.12 (36) .46 (95)
13 .29 (0) 1.08 (56) .05 (86)
16 .66 (81) .18 (98) 1.07 (81)
17 .54 (67) .28 (58) 2.03 (67)
18 .70 (99) .11 (99) 1.09 (54)
19 1.40 (59) 1.20 (101) 1.47 (61)
20 .57 (54) .24 (54) 1.04 (24)
22 1.07 (46) .45 (46) .55 (47)
a Values are highest LOD scores (location in cM), on
each chromosome, for each phenotype. Spirometric values
were adjusted for known covariates (see text).
Genotyping and Data Management
The Mammalian Genotyping Service of the National
Heart, Lung and Blood Institute performed genome-scan
genotyping in 607 individuals, using DNA that was ex-
tracted from blood samples by Puregene Kits (Gentra
Systems). We analyzed 378 autosomal STRmarkerswith
an average spacing of 9.1 cM, ranging from 7.4 cM on
chromosome 11 to 10.6 cM on chromosome 14.Marker
locations were determined on the basis of version 10 of
theMarshfield map (see the Center forMedical Genetics,
MarshfieldMedical Research Foundation,Web site). For
markers with exactly the same location on the Marsh-
field Map, a distance of 0.1 cM was placed between
these markers after relative locations on the sequence
published by the UCSC Human Genome Project Work-
ing Draft (“Golden Path”) and on the Celera Genomics
Human Genome Sequence (see the Celera Discovery Sys-
tem Web site) had been determined.
On chromosome 12, an additional 12 STR markers
were genotyped, at Brigham and Women’s Hospital. For
these additional markers, map locations were also de-
termined on the basis of the Marshfield map, with con-
firmation from the UCSC Human Genome Project
Working Draft and/or the Celera Genomics Human Ge-
nome Sequence (see the Celera Discovery System Web
site). Fluorescent-labeled and unlabeled primers were
obtained from Research Genetics and Applied Biosys-
tems. PCR was performed with Taq Gold Polymerase
(Applied Biosystems) in MJ Research PCR machines.
Product sizes were assessed on an ABI 3100. GENE-
SCAN and GENOTYPER version 3.7 software were
used to assist with genotype determination.
To test for Mendelian inconsistencies in our pedigree
data, the RELCHECK program was used to determine
pedigree relationships, on the basis of the genome-scan
marker data (Broman et al. 1998). Twenty-two subjects
failed to match reported familial relationships and were
excluded. For the remaining 585 genotyped individuals,
inconsistencies at individual markers were resolved by
the PEDCHECK program (O’Connell andWeeks 1998).
The mean rate of pedigree inconsistencies was less than
one inconsistency per marker (0.95). Marker-allele fre-
quencies were estimated by maximum-likelihood esti-
mation by the SOLAR program (Almasy and Blangero
1998).
Linkage Analysis
Phenotypes selected for linkage analysis included
FEV1, FVC, and FEV1/FVC. The primary analyses were
performed with absolute-volume measurements; con-
firmatory analyses were performed with percentage of
predicted values. The absolute spirometric values ap-
peared to be normally distributed, and tests of model fit
(with the FISHER program) suggested that the spiro-
metric variables were acceptably close to normality;
therefore, no data transformations were performed
(Lange et al. 1988). Covariate adjustments were per-
formed within the linkage analysis, as described below.
Two-point and multipoint linkage analyses of the ge-
nome-scan data were performed by a variance-compo-
nent method, as implemented in the SOLAR program
(version 1.7.4, running under Linux Mandrake version
8.0) (Almasy and Blangero 1998). SOLAR partitions
observed phenotypic variance into genetic and nonge-
netic components, by maximum-likelihoodmethods; ad-
ditive models, without dominance variance, were used
in these analyses. Each model assumed that the distri-
bution of the response phenotype in a pedigree was mul-
tivariate normal, with a mean that depended on a par-
ticular set of explanatory covariates. Genotypes were
imputed for untyped individuals, conditional on all oth-
er marker data and on pedigree structure, and marker-
specific identical by descent (IBD) matrices among all
relative pairs were estimated independently for all au-
tosomal markers. Multipoint IBD matrices were then
generated at 1-cM resolution. Expected genetic covari-
ances among relatives in an extended family were spec-
ified as a function of the fixed effects of covariates, re-
sidual error and random effects reflecting polygenic
factors, and an unobserved QTL linked to an observed
marker locus.
To adjust for the effects that demographics, body size,
and cigarette smoking had on the spirometric measure-
ments, age, sex, race, height, pack-years, age2, height2,
and pack-years2 were included as covariates in the link-
age analysis. Covariates that were significant at P !
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Figure 1 Multipoint variance-component linkage analysis of all 22 autosomes in pedigrees with early-onset COPD. Results of linkage analysis are presented for FEV1, FEV1/FVC, and FVC,
with adjustment for relevant covariates. Genetic distance (in cM), from version 10 of the Marshfield map, is plotted against variance-component LOD score. Significant linkage was demonstrated
for FEV1/FVC, on chromosome 2 (LOD score 4.12).
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Figure 2 Multipoint variance-component linkage analysis of chromosome 12, including STR markers from the initial genomewide scan,
as well as 12 additional markers. Genetic distance (in cM), from version 10 of the Marshfield map, is plotted against the multipoint variance-
component LOD score for FEV1, FEV1/FVC, and FVC. For FEV1, a maximum LOD score of 2.43 was observed at 37 cM.
were retained in the linkage-analysis model. Heri-.05
tability values were obtained by SOLAR after adjust-
ment for covariates.
The statistical associations between covariates entered
as fixed effects and the response variable were assessed
by removal of terms from the mean model and subse-
quent calculation of a likelihood-ratio x2-test statistic.
The null hypothesis of no linkage at a specific chro-
mosomal location was tested by comparison of a poly-
genic model to a model with variance components for
both a QTL and polygenic factors. Comparing the loge-
likelihood values of these twomodels gives a test statistic
that is asymptotically distributed as a mixture of dis-2x
tributions (Self and Liang 1987). A LOD score for link-
age was determined by calculating twice the difference
between the log10-likelihood values of these two models
(Almasy and Blangero 1998).
Because the pedigrees with early-onset COPD were as-
certained through single probands, the ascertainment cor-
rection provided in the SOLAR program—which involves
conditioning the pedigree likelihood on the probability of
the proband’s phenotype for each outcome—was em-
ployed (Lange et al. 1988). As noted above, pedigrees
were extended to include 49 additional individuals; the
impact that inclusion of these individuals had on the link-
age results was examined in additional linkage analyses,
which used only subjects ascertained through the fixed-
ascertainment scheme.
Simulations were performed by SOLAR, to assess the
statistical significance of the linkage results. Genotypes
for a fully informative unlinked marker were created,
and the evidence for linkage was assessed in 100,000
replicates. The number of times that a LOD score ex-
ceeded a specified threshold provides an empirical P
value for that LOD-score threshold.
Results
Demographics and Spirometry in Families
with Early-Onset COPD
A total of 607 individuals were included in the genome-
scan data set. Twenty-two subjects were removed because
of pedigree inconsistencies, and spirometric data for three
subjects were unavailable. The age, smoking history, and
spirometry (percentage of predicted values) for the 582
members of 72 pedigrees with spirometric values included
in the genome-scan linkage analyses are presented in table
1. The profound degree of airflow obstruction is evident
for probands with early-onset COPD, with mean pre-
dicted FEV1 values of andmean predicted17.3% 6.3%
FEV1/FVC values of . In severe COPD,37.4% 11.4%
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reductions in FVC also are noted; the predictedmeanFVC
in probands was . Since the risk of de-47.9% 14.7%
veloping COPD increases with age, it is not surprising
that mean spirometric values were lower in parents than
in siblings and that those in siblings were lower than those
in children.
Genomewide Multipoint Variance-Component Linkage
Analysis
Genomewide multipoint variance-component linkage
results from SOLAR, for the absolute values of FEV1,
FVC, and FEV1/FVC, are presented in figure 1 and are
summarized in table 2. In these analyses, significant cov-
ariates for age, sex, pack-years, height, sex, and quad-
ratic terms were included in the variance-component
models, to adjust for these known effects on pulmonary
function.
For FEV1, the estimated heritability was 35.3% 
6.3% ( ); significant covariates were those forP ! .0001
age ( ), sex ( ), height ( ),P ! .0001 P ! .0001 P ! .0001
pack-years ( ), and pack-years2 ( ).P ! .0001 P ! .0001
Multipoint LOD scores 11.0 were found on eight chro-
mosomes; the highest LOD score was 1.53, on chro-
mosome 12 (at 36 cM from pter).
For FVC, the estimated heritability was 31.0% 
6.2% ( ), and significant covariates were thoseP ! .0001
for age ( ), sex ( ), age2 ( ),P ! .0001 P ! .0001 Pp .0002
height ( ), pack-years ( ), pack-years2P ! .0001 P ! .0001
( ), and race ( ). Multipoint LODP ! .0001 Pp .005
scores 11.0 were found on six chromosomes; the highest
LOD score was 2.05, on chromosome 1 (at 13 cM).
For FEV1/FVC, the estimated heritability was 30.3%
 5.2% ( ); significant covariates were thoseP ! .0001
for age ( ), pack-years ( ), and pack-P ! .0001 P ! .0001
years2 ( ). Multipoint LOD scores 11.0 wereP ! .0001
found on eight chromosomes; the highest LOD score
was 4.12, on chromosome 2 (at 222 cM).
Several chromosomal regions demonstrated some evi-
dence for linkage to multiple phenotypes. For example,
the chromosome 2 region that demonstrated strong evi-
dence for linkage to FEV1/FVC also had a LOD score of
1.12 for FEV1; the chromosome 12 region with strongest
evidence for linkage to FEV1 (LOD score 1.53, at 36 cM)
provided a LOD score of 1.12 to FVC, at the same lo-
cation; the chromosome 1 region at 130–150 cM pro-
duced LOD scores 11.0 for FEV1, FVC, and FEV1/FVC;
and a broad region of chromosome 19 also demonstrated
some evidence for linkage to all three phenotypes.
However, other chromosomal regions demonstrated
linkage to only a single phenotype. For example, chro-
mosome 17 had, at 67 cM, a LOD score of 2.03 for
FEV1/FVC but much more modest LOD scores for FEV1
and FVC.
Additional Markers on Chromosome 12p:
Variance-Component Linkage Analysis
Additional STR markers on chromosome 12p were
genotyped as part of a previous study of qualitative
COPD-related phenotypes (Silverman et al. 2002).
Therefore, higher-resolution linkage analysis could be
performed in this region. Fine mapping was performed
with 4 markers (GATA49D12, Mfd259, GATA6C01,
and ATA27A06) from the original genomewide scan and
12 additional STR markers located at 18–49 cM on
chromosome 12. Because multipoint linkage analysis is
sensitive to errors in marker order and in intermarker
distances, two-point linkage analysis also was performed
in this region, by SOLAR. The maximum observed two-
point LOD score for FEV1 was 2.88 (D12S1715, at 36
cM), that for FVC was 1.95 (D12S1581, at 30 cM), and
that for FEV1/FVC was 2.68 (D12S1066, at 42 cM).
The multipoint variance-component linkage-analysis
results for chromosome 12, including the 12 additional
flanking markers on 12p, are depicted in figure 2. Com-
pared with the initial genomewide multipoint linkage
analysis, increased evidence for linkage was noted for
FEV1 and FEV1/FVC. For FEV1, the maximummultipoint
LOD score was 2.43, at 37 cM, and, for FEV1/FVC, the
maximum multipoint LOD score was 1.84, at 38 cM.
With the additional STR markers on 12p, the maximum
LOD score for FVC—1.12, at 36 cM—remained un-
changed from the initial genomewide scan.
Confirmatory Analyses
Several additional analyses were performed. Pulmo-
nary function test values are typically expressed as a
percentage of predicted values, to adjust for the known
effects that age, height, sex, and race have on these mea-
surements. Therefore, we also performed linkage anal-
ysis using percentage of predicted values; in these anal-
yses, pack-years (but not age, height, sex, or race) were
included as a covariate, to adjust for the effects of cig-
arette smoking. The genomewide linkage-analysis re-
sults when values expressed as percentage of predicted
values were used were not substantially different from
the results when absolute volumes were used (results not
shown).
Additional confirmatory analyses were performed to
assess the impact that ascertainment had on the linkage
results. Phenotypic values for the 49 subjects enrolled in
the study who did not meet the strict ascertainment
scheme including all first-degree relatives and all older
second-degree relatives (i.e., aunts, uncles, grandparents,
and half sibs) were excluded, and the genome-scan link-
age analysis was repeated. The linkage-analysis results
for these “trimmed” pedigrees were generally quite sim-
ilar to those for the analyses using all subjects.
To estimate the statistical significance of the FEV1/
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FVC linkage results, simulations were performed with a
fully informative unlinked marker, followed by variance-
component linkage analysis of the FEV1/FVC phenotype
for each replicate. The highest observed two-point LOD
scores in the FEV1/FVC linkage analysis were 2.99, for
GATA23D03 (chromosome 2, at 227 cM), and 2.68, for
ATC6A06 (chromosome 17, at 67 cM). In 100,000 rep-
licates of an unlinked marker, LOD scores 12.68 were
observed 41 times; thus, the empirical P value for the
ATC6A06 linkage to FEV1/FVC is .0004. LOD scores
12.99 were observed 20 times, for an empirical P value,
for the GATA23D03 linkage, of .0002. Although the
simulations were based on two-point linkage analysis,
it is of interest that the maximum multipoint LOD score
for FEV1/FVC (LOD score 4.12), on chromosome 2, was
exceeded in only 2 of 100,000 simulations.
Discussion
Although the development of COPD is clearly influenced
by cigarette smoking, genetic determinants are likely to
be important as well. To enrich the sample for potential
genetic determinants, we have studied extended pedi-
grees of individuals ascertained through probands with
severe early-onset COPD without severe AAT deficiency.
Our 10-cM genomewide linkage scan is the first reported
investigation of linkage to quantitative spirometric mea-
sures in pedigrees with COPD. The highest observed
LOD score was 4.12, for FEV1/FVC, on chromosome
2q. On the basis of standard criteria for linkage-analysis
results in extended pedigrees (i.e., LOD score 1.9 for
suggestive linkage and LOD score 3.3 for significant
linkage), this result corresponds to significant linkage
(Lander and Kruglyak 1995). The most promising evi-
dence for linkage to FEV1 was found on chromosome
12p, in the initial genomewide scan; with the inclusion
of 12 additional markers on 12p, the maximum LOD
score for FEV1 was 2.43, which corresponds to sugges-
tive linkage. In addition, suggestive linkage to FEV1/FVC
was found on chromosomes 17 (LOD score 2.03, at 67
cM) and 1 (LOD score 1.92, at 120 cM), and suggestive
linkage to FVCwas found on chromosome 1 (LOD score
2.05, at 13 cM).
In a previous genomewide linkage scan of these fam-
ilies with early-onset COPD, we studied qualitative phe-
notypes, including moderate airflow obstruction (FEV1
!60% of predicted value, with FEV1/FVC !90% of pre-
dicted value) and mild airflow obstruction (FEV1 !80%
of predicted value, with FEV1/FVC !90% of predicted
value) (Silverman et al. 2002). For these qualitative phe-
notypes, the highest observed LOD scores for moderate
airflow obstruction were 1.70, on chromosome 12p (at
36 cM), and 1.54, on chromosome 19 (at 42 cM); those
regions also provided several of the highest LOD scores
for mild airflow obstruction in smokers. When addi-
tional STR markers on 12p were included, the maxi-
mum LOD score for moderate airflow obstruction,
when nonparametric methods were used, was 2.13. Of
interest, in the current analysis of quantitative pheno-
types, chromosomes 12 and 19 also provide the highest
LOD scores for FEV1, suggesting that those loci may be
involved in airflow obstruction.
In the qualitative-phenotype linkage analysis, no sig-
nificant evidence for linkage to chromosome 2q was
observed: the maximum LOD score for moderate air-
flow obstruction was 0.11, at 237 cM, and the maxi-
mum LOD score for mild airflow obstruction was 0.14,
at 167 cM; however, in the present analysis, significant
evidence for linkage of FEV1/FVC (LOD score 4.12, at
222 cM) and nominal evidence for linkage of FEV1
(LOD score 1.12, at 222 cM) were observed. The chro-
mosome 2q locus may represent an airflow-obstruction
locus, and quantitative phenotypes may be more pow-
erful at detection of such loci. In particular, the FEV1/
FVC ratio may detect earlier airflow obstruction, before
significant reductions in FEV1 are observed. Alterna-
tively, the chromosome 2q linkage may represent a locus
that influences the development of dysanapsis, which is
defined as differences from the normal relationship be-
tween airway size and lung size (Mead 1980). Regard-
less of whether the chromosome 2q linkage to FEV1/
FVC represents a gene that influences lung growth and
dysanapsis or the early development of smoking-related
airflow obstruction, reduction in FEV1/FVC has been
shown to be associated with subsequent decline in pul-
monary function (Burrows et al. 1987); therefore, ge-
netic determinants of FEV1/FVC likely represent im-
portant determinants of COPD.
Subjects with severe COPD may develop reductions
in FVC as well as in FEV1. However, compared to FEV1,
FVC tends to be relatively preserved in COPD, leading
to a reduction in the FEV1/FVC ratio, as a cardinal
feature of COPD. Therefore, it is of interest that some
regions of nominal linkage to FVC, such as those on
chromosomes 8 and 12, showed LOD scores 11.0, for
both FEV1 and FVC, whereas other regions, such as
that on chromosome 11, only showed evidence for
linkage to FVC. Further investigation will be neces-
sary to determine whether regions of linkage to both
FEV1 and FVC represent genetic determinants of lung
size whereas regions of linkage to FEV1 and FEV1/
FVC—but not to FVC—represent genetic determinants
of airway obstruction.
In genomewide linkage studies, multiple genomic
regions have been linked to asthma-related phenotypes.
Evidence for linkage of asthma-related phenotypes to
the two most promising regions in this study, chro-
mosome 2q and chromosome 12p, have been reported
elsewhere, in some asthma-genetics studies. Nominal
evidence for linkage to chromosome 2q ( ) wasP ! .05
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demonstrated for asthma diagnosis in the Collaborative
Study of the Genetics of Asthma, for IgE levels in the
German Asthma Genetics Study, for airway responsive-
ness and eosinophil counts in the French Asthma Ge-
netics Study, and for allergy skin tests in the Hutterites
(Daniels et al. 1996; Collaborative Study on the Ge-
netics of Asthma 1997; Wjst et al. 1999; Dizier et al.
2000; Ober et al. 2000). On chromosome 12p, several
previous asthma-genetics studies have found nominal
evidence for linkage to asthma and atopy-related phe-
notypes in the same general region that, in our study,
demonstrates linkage to FEV1 (Collaborative Study on
the Genetics of Asthma 1997; Blumenthal et al. 1998).
It remains unclear whether asthma and COPD share
genetic determinants, and elucidation of the specific ge-
netic determinants of each condition will be necessary
to resolve this controversy definitively. However, our
results are consistent with the possibility that at least
some genetic determinants are shared by asthma and
COPD.
Several biologically plausible candidate genes are lo-
cated within the two chromosomal regions that aremost
promising in our analysis (the candidate-gene locations
were obtained from the April 2001 freeze at the UCSC
Human Genome Project Working Draft [“Golden
Path”] Web site). The interleukin-8 receptor alpha gene
(IL8RA) is located within the region of linkage to FEV1/
FVC, on chromosome 2q. Interleukin-8 is a cytokine
involved in neutrophil recruitment to the lung, which
could lead to increased delivery of neutrophil proteases
and to increased risk for lung-elastin destruction (Bag-
giolini et al. 1989). Microsomal glutathione S-transfer-
ase 1 (MGST1), an enzyme involved in the detoxifica-
tion of oxygen radicals such as the reactive species
produced by cigarette smoke, and matrix Gla protein
(MGP), a lung extracellular-matrix component that is
mutated in a syndrome (i.e., Keutel syndrome) including
diffuse pulmonary calcification, are located near the re-
gion of strongest evidence for linkage to FEV1, on chro-
mosome 12p (Munroe et al. 1999; Kelner et al. 2000).
This study has several significant limitations. The ge-
neralizability of linkage results in the families with severe
early-onset COPD to COPD at later ages is undeter-
mined. We have included the primary environmental de-
terminant of COPD, cigarette smoking, as a covariate in
our analyses, but we have not formally tested for ge-
notype # environment interactions. Our ascertainment
scheme did include single probands, but additional ex-
tended relatives were included in some families; how-
ever, the linkage results were not significantly altered
when these additional relatives were excluded. Finally,
we have not adjusted for the multiple phenotypes ana-
lyzed, because these spirometric phenotypes are signifi-
cantly correlated.
There are likely to be multiple genetic determinants
of COPD, and these linkage analyses of quantitative
spirometric phenotypes have identified both one region
of significant linkage and several regions of suggestive
linkage, on which to focus fine-mapping efforts. Both
the use of additional STR markers to evaluate the
regions of linkage that have been observed in our study
and replication of our findings in other samples will be
necessary. If novel genetic determinants of COPD can
be identified, important new insights into COPD path-
ophysiology—and, ultimately, treatment—could result.
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